A Medtronic insider sale disclosed on October 16, 2026, involved Chairman and Chief Executive Geoffrey Martha selling 50,000 shares at $95 each. The reported transaction took place on October 15 and totaled $4.75 million.
Key Takeaways
- Martha’s reported sale totaled $4.75 million before any fees or taxes.
- The SEC ownership disclosure was filed one day after the transaction.
- The sale alone does not establish management’s view of Medtronic’s prospects.
Table of Contents
- Medtronic insider sale separates trade and disclosure dates
- What the transaction does not establish
- Conclusion
Medtronic insider sale separates trade and disclosure dates
The SEC’s October 16 Form 4 filing record identifies Martha as the reporting person and Medtronic as the issuer, with October 15, 2026, listed as the reporting period. That distinction separates the ownership change from the date it was publicly disclosed.
The filing-detail page confirms the identities and dates but does not display the underlying transaction table. It therefore does not independently establish the reported 50,000-share quantity or $95 execution price.
Multiplying the reported share count by the price gives gross proceeds of $4.75 million. These are proceeds from an executive’s personal share sale, not revenue or capital raised by Medtronic.
| Item | Details |
|---|---|
| Shares sold | 50,000 |
| Reported execution price | $95 per share |
| Gross transaction value | $4.75 million |
What the transaction does not establish
The available transaction information does not establish Martha’s reason for selling, whether the sale followed a prearranged trading plan, or how many shares he retained. Without a remaining ownership balance, the sale cannot be expressed reliably as a percentage of his holding.
An insider sale also does not, by itself, demonstrate a change in a company’s operating outlook or dividend capacity. Those questions require financial results, cash-flow information and company announcements rather than an inference from a personal ownership transaction.
Conclusion
The confirmed disclosure date is October 16, 2026. Remaining ownership and any trading-plan details are the next information to check before drawing broader conclusions from the reported sale.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
